Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cai Sun

Showing results (181-190 of 194) with videos related to

Pageof 20
Sort By:
Frontiers in Immunology|November 15, 2021
Humanized Anti-CD19 CAR-T Cell Therapy and Sequential Allogeneic Hematopoietic Stem Cell Transplantation Achieved Long-Term Survival in Refractory and Relapsed B Lymphocytic Leukemia: A Retrospective Study of CAR-T Cell TherapyWei Chen, Yuhan Ma, Ziyuan Shen, et al.
Cytotherapy|April 16, 2024
Complex association of body mass index and outcomes in patients with relapsed and refractory multiple myeloma treated with CAR-T cell immunotherapyHai Cheng, Yingjun Sun, Xiaoxue Zhang, et al.
Cytotherapy|September 16, 2024
Comprehensive characterization of cytopenia after chimeric antigen receptor-T cell infusion in patients with relapsed or refractory multiple myelomaHai Cheng, Lingyan Shao, Dandan Wang, et al.
American Journal of Hematology|July 31, 2015
MicroRNA-181a, a potential diagnosis marker, alleviates acute graft versus host disease by regulating IFN-γ productionWei Sang, Cong Zhang, Dianzheng Zhang, et al.
Clinical and Experimental Medicine|September 4, 2024
Enhanced platelet function through CAR-T cell therapy in relapsed/refractory multiple myelomaRuixue Ma, Qi Zhang, Yang Liu, et al.
International Urology and Nephrology|May 1, 2025
Nephrotoxicity of CAR-T therapy in patients with relapsed and refractory multiple myelomaZihan Chen, Yegan Chen, Jiaying Liu, et al.
Clinical and Experimental Medicine|November 1, 2023
Long-term analysis of cellular immunity in patients with RRMM treated with CAR-T cell therapyHai Cheng, Shengwei Ji, Jiaojiao Wang, et al.
The American Journal of Surgical Pathology|August 25, 2022
Clinicopathologic Features and Genomic Signature of De Novo CD5 + Diffuse Large B-Cell Lymphoma : A Multicenter Collaborative StudyWei Sang, Yuhan Ma, Xiangmin Wang, et al.
Cancer Medicine|July 2, 2020
Phase II trial of co-administration of CD19- and CD20-targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphomaWei Sang, Ming Shi, Jingjing Yang, et al.
The New Phytologist|October 16, 2023
Global analysis of seed transcriptomes reveals a novel PLATZ regulator for seed size and weight control in soybeanYang Hu, Yue Liu, Long Lu, et al.
Pageof 20

Showing results (181-190 of 194) with videos related to

Sort By:
Pageof 20
Frontiers in Immunology|November 15, 2021
Humanized Anti-CD19 CAR-T Cell Therapy and Sequential Allogeneic Hematopoietic Stem Cell Transplantation Achieved Long-Term Survival in Refractory and Relapsed B Lymphocytic Leukemia: A Retrospective Study of CAR-T Cell TherapyWei Chen, Yuhan Ma, Ziyuan Shen, et al.
Cytotherapy|April 16, 2024
Complex association of body mass index and outcomes in patients with relapsed and refractory multiple myeloma treated with CAR-T cell immunotherapyHai Cheng, Yingjun Sun, Xiaoxue Zhang, et al.
Cytotherapy|September 16, 2024
Comprehensive characterization of cytopenia after chimeric antigen receptor-T cell infusion in patients with relapsed or refractory multiple myelomaHai Cheng, Lingyan Shao, Dandan Wang, et al.
American Journal of Hematology|July 31, 2015
MicroRNA-181a, a potential diagnosis marker, alleviates acute graft versus host disease by regulating IFN-γ productionWei Sang, Cong Zhang, Dianzheng Zhang, et al.
Clinical and Experimental Medicine|September 4, 2024
Enhanced platelet function through CAR-T cell therapy in relapsed/refractory multiple myelomaRuixue Ma, Qi Zhang, Yang Liu, et al.
International Urology and Nephrology|May 1, 2025
Nephrotoxicity of CAR-T therapy in patients with relapsed and refractory multiple myelomaZihan Chen, Yegan Chen, Jiaying Liu, et al.
Clinical and Experimental Medicine|November 1, 2023
Long-term analysis of cellular immunity in patients with RRMM treated with CAR-T cell therapyHai Cheng, Shengwei Ji, Jiaojiao Wang, et al.
The American Journal of Surgical Pathology|August 25, 2022
Clinicopathologic Features and Genomic Signature of De Novo CD5 + Diffuse Large B-Cell Lymphoma : A Multicenter Collaborative StudyWei Sang, Yuhan Ma, Xiangmin Wang, et al.
Cancer Medicine|July 2, 2020
Phase II trial of co-administration of CD19- and CD20-targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphomaWei Sang, Ming Shi, Jingjing Yang, et al.
The New Phytologist|October 16, 2023
Global analysis of seed transcriptomes reveals a novel PLATZ regulator for seed size and weight control in soybeanYang Hu, Yue Liu, Long Lu, et al.
Pageof 20